Michael D Miller

发表

Genetic basis of variation in tenofovir drug susceptibility in HIV-1

Fraser I Lewis, F. Lewis, Robert J Murray, 2008, AIDS.

K65R, TAMs and tenofovir.

Michael D Miller, M. Miller, Michael D. Miller, 2004, AIDS reviews.

Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant.

Michael Rowley, Michael D. Miller, M. Rowley, 2006, Bioorganic & medicinal chemistry letters.

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.

Stefan Zeuzem, Steven Knox, A. Mangia, 2017, Journal of hepatology.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Gennaro Ciliberto, Peter S Kim, Simon Lennard, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.

Tao Ji, William Morris, M Katharine Holloway, 2017, ACS medicinal chemistry letters.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.

Karen Holmes, Kathy Lyons, Joseph Kessler, 2004, Bioorganic & medicinal chemistry letters.

Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay.

D. Hazuda, M. Lai, Michael D Miller, 2008, Analytical biochemistry.

Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro

J. Shiver, V. Garsky, M. Citron, 2002, The Journal of Biological Chemistry.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Adriano Lazzarin, Edwin DeJesus, Peter Sklar, 2009, The Lancet.

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

C. Gibbs, Huiling Yang, W. Delaney, 2002, Hepatology.

Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody

M. Luftig, R. Geleziunas, A. Carfi, 2006, Nature Structural &Molecular Biology.

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

Katyna Borroto-Esoda, P. Marcellin, K. Kitrinos, 2011, Hepatology.

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.

H. Mo, K. Kowdley, B. Doehle, 2017, Journal of Hepatology.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.

Karen Holmes, Joseph Kessler, Anthony Carella, 2004, Bioorganic & medicinal chemistry letters.

Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion.

Gennaro Ciliberto, R. Cortese, G. Ciliberto, 2003, Journal of molecular biology.

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

Mark Embrey, Samson M Jolly, Wei Xu, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Joel E Gallant, Edwin DeJesus, Schlomo Staszewski, 2004, JAMA.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Jing Zhao, Christine Katlama, Benjamin Young, 2011, The Lancet. Infectious diseases.